{"title":"Revolutionizing hypertension treatment: aprocitentan's dual action against resistant hypertension.","authors":"Amirhossein Sahebkar, Ali H Eid","doi":"10.1080/17474086.2025.2500607","DOIUrl":"10.1080/17474086.2025.2500607","url":null,"abstract":"","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"443-446"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mridul Makkar, Mullai S Dhinakaran, Prateek Shukla, Diksha Sarwan, Soumya Ojha, M Joseph John
{"title":"Effectiveness of myofascial therapy (MFT) along with traditional physiotherapy and intermittent prophylaxis on short-term improvement of joint health in hemophilic arthropathy: a randomized control trial.","authors":"Mridul Makkar, Mullai S Dhinakaran, Prateek Shukla, Diksha Sarwan, Soumya Ojha, M Joseph John","doi":"10.1080/17474086.2025.2495674","DOIUrl":"10.1080/17474086.2025.2495674","url":null,"abstract":"<p><strong>Background: </strong>Myofascial therapy (MFT) works on biomechanical soft tissue loading principles aimed to reduce pain, improve tissue mobility and function.</p><p><strong>Aim: </strong>To find effectiveness of MFT and traditional physiotherapy with intermittent prophylaxis on short-term improvement of joint health in hemophilic arthropathy.</p><p><strong>Research design and methods: </strong>Thirty-one patients with Hemophilia A and joint arthropathy (elbows and/or knees) were randomly divided into MFT group (MFT + traditional physiotherapy) and control group (traditional physiotherapy). Both groups received four physiotherapy sessions per week for three weeks and FVIII prophylaxis twice weekly. Haemophilia Joint Health Score (HJHS), Functional Independence Scoring for Haemophilia (FISH), and Range of Motion (ROM) were assessed on Day 0, 10, 21.</p><p><strong>Results: </strong>MFT group demonstrated a significant improvement in their overall HJHS scores (<i>p</i> = 0.016, d = 0.93) and HJHS knee joint scores (<i>p</i> = 0.007, d = 0.57) compared to control group participants. ROM increased substantially in MFT group relative to control group (18.97%; 10.10% improvement in knee and elbow ROM, respectively, vs 9.49%; 1.25%). There was an improvement in FISH scores in both groups, with a slightly greater improvement in control group (13.68% vs 11.08%).</p><p><strong>Conclusions: </strong>MFT is effective and feasible in short-term improvement of joint health in Hemophilia A patients with elbow and knee arthropathy.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"471-479"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"PRDX6 knockdown sensitizes multiple myeloma cells to ferroptosis through inactivation of the PI3K/AKT pathway.","authors":"Guifang Hu, Hongju Zhang, Yun Wang, Jingfeng Lu, Ke Dong, Wu Gao","doi":"10.1080/17474086.2025.2492881","DOIUrl":"10.1080/17474086.2025.2492881","url":null,"abstract":"<p><strong>Background: </strong>This study probes into the impact and mechanisms of PRDX6 on ferroptosis multiple myeloma (MM).</p><p><strong>Research design and methods: </strong>PRDX6 expression in MM cells were determined using Western blotting and qRT-PCR. MM cells were treated with pLKO-shPRDX6 vectors expressing PRDX6 shRNA alone or in combination with Erastin/ferrostatin-1 (ferroptosis activator/inhibitor) or 740Y-P (PI3K/AKT pathway activator). Cell viability, apoptosis, Fe<sup>2+</sup> concentration, and ROS levels were examined using CCK-8, flow cytometric analysis, iron ion detection, and DCFH-DA assay, and ELISA. Malondialdehyde (MDA) and glutathione (GSH) levels were tested with ELISA, and SLC7A11 and GPX4 levels were measured with Western blotting.</p><p><strong>Results: </strong>PRDX6 expression was sharply increased in MM cells (<i>p</i> < 0.01). Silencing of PRDX6 sensitized MM cells to ferroptosis, as indicated by elevated Fe<sup>2+</sup>, ROS, and MDA levels but decreased GSH, SLC7A11, and GPX4 levels (<i>p</i> < 0.05), and these trends were neutralized by 740Y-P treatment. Furthermore, PRDX6 knockdown lowered the levels of PI3K/AKT pathway-associated molecules (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>PRDX6 knockdown may exert pro-ferroptotic effects through inactivation of the PI3K/AKT pathway, underlying an appealing therapeutic target for MM.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-10"},"PeriodicalIF":2.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guo-Sheng Li, Tao Huang, Jing-Xiao Li, Jun Liu, Xiang Gao, Guan-Qiang Yan, Nuo Yang, Hua-Fu Zhou
{"title":"Correlation between hematocrit and the risk of common human cancers: results of a 1999-2020 observational survey and Mendelian randomization analysis.","authors":"Guo-Sheng Li, Tao Huang, Jing-Xiao Li, Jun Liu, Xiang Gao, Guan-Qiang Yan, Nuo Yang, Hua-Fu Zhou","doi":"10.1080/17474086.2025.2486381","DOIUrl":"10.1080/17474086.2025.2486381","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have underscored the significance of hematocrit (HCT) in different tumors. However, further research is needed to explore its causal relationship with various tumors.</p><p><strong>Research design and methods: </strong>A retrospective analysis and a Mendelian randomization analysis were conducted on a sample of 3,580,275 samples to investigate the causal relationships between high HCT levels and the risks of developing the 15 prevalent malignant tumors. Additionally, using an in-house cohort, Kaplan-Meier curves were utilized to examine the relationship between HCT levels and the prognosis of patients with prostate cancer (PCa).</p><p><strong>Results: </strong>An elevated HCT level was identified as a protective factor against six types of cancers, including PCa (odds ratio [OR] < 1.000, <i>p</i> < 0.05), and a risk factor for cervical cancer, melanoma, and non-melanoma skin cancer (OR > 1.000, <i>p</i> < 0.05). A potential causal association was found between high HCT levels and decreased risks of developing PCa (OR = 0.887, <i>p</i> < 0.05) and breast cancer (OR = 0.893, <i>p</i> < 0.05). HCT was identified as a protective factor against PCa (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>This study identified significant associations between HCT and nine tumors. HCT levels may serve as a protective factor against PCa.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"333-344"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kristin M Zimmerman Savill, Jonathan K Kish, Choo Hyung Lee, Prathamesh Pathak, Paul D'Amico, Alexander Russell-Smith, Ajeet Gajra
{"title":"Real-world (RW) study of outcomes for acute myeloid leukemia (AML) patients treated with glasdegib or venetoclax in US community oncology practices.","authors":"Kristin M Zimmerman Savill, Jonathan K Kish, Choo Hyung Lee, Prathamesh Pathak, Paul D'Amico, Alexander Russell-Smith, Ajeet Gajra","doi":"10.1080/17474086.2025.2492886","DOIUrl":"10.1080/17474086.2025.2492886","url":null,"abstract":"<p><strong>Background: </strong>Glasdegib (GLAS) and venetoclax (VEN) are approved in the US for treating AML in patients aged 75+ or with comorbidities precluding intensive induction chemotherapy. Community oncology outcomes for these therapies are limited.</p><p><strong>Research design and methods: </strong>This retrospective chart review summarized characteristics, treatment patterns, and outcomes of US patients treated with first-line (1 L) GLAS or VEN for AML using descriptive statistics. The study was not designed or powered to compare GLAS and VEN cohorts.</p><p><strong>Results: </strong>Among 50 patients receiving 1 L GLAS (82.0% with low-dose cytarabine), 50.0% achieved complete remission (CR), morphological leukemia-free state (MLFS), or partial response (PR). Median overall survival (OS) was 6.9 months (95% CI: 5.4-8.9). A trial-matched GLAS cohort represented 80.0% of all GLAS-treated patients in the study. Among 83 patients receiving 1 L VEN (94.0% with a hypomethylating agent), 51.8% achieved CR, MLFS, or PR, median OS was 8.4 months (95% CI: 5.7-16.2), and 31.3% met pivotal trial eligibility criteria.</p><p><strong>Conclusions: </strong>This observational study supports the clinical benefit of GLAS and VEN in treating AML patients in the real-world setting.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"399-407"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions.","authors":"Hongju Zhang, Yuting Yan, Shuhua Yi, Qi Sun","doi":"10.1080/17474086.2025.2492936","DOIUrl":"10.1080/17474086.2025.2492936","url":null,"abstract":"<p><strong>Introduction: </strong>CD30 is a transmembrane protein of the tumor necrosis factor receptor superfamily. It is expressed on a small subset of activated T and B lymphocytes, and various lymphoid neoplasms, including classical Hodgkin lymphoma and many non-Hodgkin lymphomas in both pediatric and adult populations.</p><p><strong>Areas covered: </strong>This review delves into the significance of CD30 as a therapeutic target and a prognostic indicator for various lymphomas. It provides a comprehensive overview of anti-CD30 therapeutic interventions developed to date, offering insights into the future direction of lymphoma treatment research. Literature search was conducted from January 1987 to December 2024 using PubMed, Scopus, and Web of Science databases to identify relevant studies.</p><p><strong>Expert opinion: </strong>CD30 has emerged as a critical marker of diagnosis, prognosis, and therapeutic strategies of lymphomas. The introduction of brentuximab vedotin (BV) (Adcetris), an antibody-drug conjugate targeting CD30, has significantly advanced the treatment landscape for multiple lymphoma types, demonstrating enhanced efficacy and manageable safety profiles in CD30+ lymphomas patients. However, drug resistance is observed in few patients. Concurrently, innovative therapeutic strategies targeting CD30, such as chimeric antigen receptor T-cells therapies and bispecific antibodies, are in development. This underscores a strong and ongoing research effort aimed at improving the management of patients with CD30+ lymphomas.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"373-386"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Louise Damian, Vincent Langlois, Fabrice Jardin, Jean-Marc Kerleau, Maximilien Grall, Hervé Levesque, Ygal Benhamou, Gaëtan Sauvetre
{"title":"Predictors of progression to chronicity in newly diagnosed primary immune thrombocytopenia: a retrospective multicenter French study.","authors":"Louise Damian, Vincent Langlois, Fabrice Jardin, Jean-Marc Kerleau, Maximilien Grall, Hervé Levesque, Ygal Benhamou, Gaëtan Sauvetre","doi":"10.1080/17474086.2025.2495669","DOIUrl":"10.1080/17474086.2025.2495669","url":null,"abstract":"<p><strong>Background: </strong>The long-term outcome of primary immune thrombocytopenia (ITP) is unpredictable. Chronic ITP is common in adults, requiring second-line treatments with increased morbidity and mortality. Our study aimed to identify predictive factors of chronicity at the time of diagnosis in primary adult ITP.</p><p><strong>Research design and methods: </strong>This retrospective multicenter study included adult patients newly diagnosed with primary ITP. Patients with a normal platelet count and no ongoing medication twelve months after disease onset were categorized in the complete remission ITP group, otherwise in the chronic ITP group.</p><p><strong>Results: </strong>219 patients were included, 110 in the complete remission ITP group and 109 in the chronic ITP group. In multivariate analysis, predictive factors of progression to chronicity included the absence of an infectious event preceding ITP onset (p = 0.048), the absence of bleeding manifestations (p = 0.002) and a platelet count >10 x 109/L at disease onset (p = 0.02). A poor response to initial corticosteroid treatment was also associated with chronicity, including corticosteroid dependence (p<0.001) and corticosteroid resistance (p = 0.001).</p><p><strong>Conclusions: </strong>In this retrospective French cohort, predictors of chronicity in newly diagnosed primary adult ITP included the absence of preceding infectious event, platelet >10 x 109/L and absence of bleeding manifestations at onset.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"409-415"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonella Meloni, Vincenzo Positano, Paolo Ricchi, Alessia Pepe, Riccardo Cau
{"title":"What is the importance of monitoring iron levels in different organs over time with magnetic resonance imaging in transfusion-dependent thalassemia patients?","authors":"Antonella Meloni, Vincenzo Positano, Paolo Ricchi, Alessia Pepe, Riccardo Cau","doi":"10.1080/17474086.2025.2486379","DOIUrl":"10.1080/17474086.2025.2486379","url":null,"abstract":"<p><strong>Introduction: </strong>Iron overload is the main pathophysiological driver of organ damage in transfusion-dependent thalassemia (TDT). Magnetic resonance imaging (MRI) provides detailed insights into the distribution and severity of iron accumulation in the different organs.</p><p><strong>Areas covered: </strong>This special report describes the impact of MRI on clinical and therapeutic management and short- and long-term outcomes in TDT patients. PubMed, Scopus, and Google Scholar databases were searched to identify the relevant studies published before November 2024.</p><p><strong>Expert opinion: </strong>Cardiac and hepatic MRI are now well-established modalities, integrated into the clinical practice. They have become essential for tailoring iron chelation therapies to the specific patient's needs and for monitoring treatment efficacy. The improved control of cardiac iron burden has translated into reduced morbidity and mortality. The MRI accessibility remains limited in resource-limited settings and progress in this field relies on educating and training centers to ensure accurate execution and interpretation. The clinicopathological significance, prognostic value, and reproducibility of pancreatic iron levels assessment have been established, charting a path toward its clinical use. There are limited data about renal, adrenal, and pituitary iron deposition, and more research is needed to fully establish the functional significance and to standardize and validate the MRI protocols.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"291-299"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Five decades of successive establishment of hemophilia care in Thailand.","authors":"Ampaiwan Chuansumrit, Thip Sriphaisal, Triroj Krutvecho, Nongnuch Sirachainan, Pimpun Kitpoka, Monratta Pitakcharoen, Suphaneewan Jaovisidha, Panyu Panburana, Monthon Suwannuraks, Nantana Sri-Udomporn, Chusak Kijkunasathian, Rungrote Nateserinilkul, Bunchoo Pongtanakul, Chanchai Traivaree, Patcharee Komvilaisak, Darintr Sosothikul, Yujinda Lektrakul, Thunyakorn Nuntiyagul, Pacharapan Surapolchai, Natsaruth Songthawee, Ekawat Suwantaroj, Pantep Angchaisuksiri, Theera Ruchutrakul, Ponlapat Rojnuckarin","doi":"10.1080/17474086.2025.2486378","DOIUrl":"10.1080/17474086.2025.2486378","url":null,"abstract":"<p><strong>Introduction: </strong>Management of patients with hemophilia in healthcare resource limited countries is challenging for healthcare providers.</p><p><strong>Area covered: </strong>Thai patients with hemophilia initially received episodic treatment of cryoprecipitate and fresh frozen plasma (FFP) in 1965. Home treatment using cryoprecipitate at early bleeding episodes was initiated in 1979 and replaced with fresh dry plasma in 1982. Heat-treated, lyophilized cryoprecipitate commenced in 1997, and factor concentrate was imported for clinical use in 2000. A healthy diet, limit weight gain and exercise for the prominent vein constitute a commitment among every hemophiliac. National advocacy of home treatment using factor concentrates at early bleeding episodes started in 2006 and nationwide low-dose prophylaxis in 2018. Immune tolerance induction (ITI) was initially attempted in 1997. The dental splint was invented as a local measure for dental procedures in 1979, and fibrin glue has been applied to surgical sites. A computerized program for hereditary bleeding disorders registry was initiated in 1999 and became nationwide in 2020. Finally, nationwide nonfactor therapy of monthly low-dose emicizumab prophylaxis will be established soon.</p><p><strong>Expert opinion: </strong>Hemophilia care in Thailand constitutes the real-world experience passing from generation to generation for five decades using our limited resources efficiently.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"309-321"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comprehensive review of morphological diagnosis of adult T-cell leukemia-lymphoma.","authors":"Shigeo Fuji, Masakazu Muta, Tomoko Hisakata, Noriaki Kawano, Eiichirou Ikeda, Hiroyoshi Kouno, Yuya Tanabe, Kayoko Nakanishi","doi":"10.1080/17474086.2025.2490759","DOIUrl":"10.1080/17474086.2025.2490759","url":null,"abstract":"<p><strong>Introduction: </strong>Adult T-cell leukemia-lymphoma (ATL) is a rare hematological malignancy associated with human T-cell leukemia virus type 1 (HTLV-1) infection. Accurate diagnosis and classification of ATL clinical subtypes rely on the identification of abnormal lymphocytes in peripheral blood smears. However, the diverse morphology of ATL cells and lack of standardized evaluation criteria worldwide can pose challenges.</p><p><strong>Area covered: </strong>This review consolidates expert opinions from clinical laboratory technologists experienced in the diagnosis of ATL. Here, we present the characteristic features of ATL cells and the common pitfalls encountered in clinical practice. In acute-type ATL, the 'flower cell' with its deeply lobulated, petal-like nucleus is a hallmark feature. While highly diagnostic, flower cells may not be abundant in all samples, and cells with minimal nuclear atypia can coexist. Chronic-type ATL is often characterized by small ATL cells with nuclear indentations or twists and hyperchromatic chromatin. Smoldering-type ATL cells share a similar morphology but generally exhibit milder nuclear atypia.</p><p><strong>Expert opinion: </strong>This review would facilitate the identification of ATL cells in routine clinical practice and serves as a foundation for future discussion and standardization of morphological criteria for ATL diagnosis.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"301-307"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}